Skip to main content

Drug Interactions between pramlintide and turmeric

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

pramlintide turmeric

Applies to: pramlintide and turmeric

MONITOR: Coadministration of turmeric with antidiabetic drugs might potentiate the risk of hypoglycemia. Some small studies have shown that curcumin, the main component in turmeric, can reduce the blood levels of glucose and/or glycosylated hemoglobin (HbA1c) in diabetic patients. In a pharmacokinetic study involving eight type-2 diabetic patients, curcumin (475 mg daily) also increased glyburide (5 mg daily) blood levels by 12% at 2 hours after glyburide administration. The combination of glyburide and curcumin significantly decreased plasma glucose levels for up to 24 hours compared to glyburide alone. However, no patient experienced hypoglycemia.

MANAGEMENT: Caution is recommended if turmeric is coadministered with antidiabetic drugs. Blood glucose should be monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.

References (4)
  1. Neerati R, Devde R, Gangi AK (2014) "Evaluation of the effects of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus." Phytother Res, 28, p. 1796-1800
  2. Adibian M, Hodaei H, Nikpayam O, Sohrab G, Hekmatdoost A, Hedayati M (2019) "The effects of curcumin supplementation on high-sensitivity C-reactive protein, serum adiponectin, and lipid profile in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial." Phytother Res, 33, p. 1374-83
  3. Chuengsamarn S, Rattanamongkolgul s, Luechapudiporn R, Phisalaphong C, Jirawatnotai S (2012) "Curcumin extract for prevention of type 2 diabetes." Diabetes Care, 35, p. 2121-7
  4. Hodaei H, Adibian M, Nikpayam O, Hedayati M, Sohrab G (2019) "The effect of curcumin supplementation on anthropometric indices, insulin resistance and oxidative stress in patients with type 2 diabetes: a randomized, double-blind clinical trial." Diabet Metab Syndr, 11, e-collection 2019

Drug and food interactions

Moderate

pramlintide food

Applies to: pramlintide

ADJUST DOSING INTERVAL: Pramlintide slows gastric emptying and may delay the absorption of concomitantly administered oral medications. In a pharmacokinetic study of 24 patients with type 2 diabetes, coadministration with pramlintide (120 mcg) decreased the peak plasma concentration (Cmax) of acetaminophen (1000 mg) by 29% and increased its time to peak plasma concentration (Tmax) based on the time of acetaminophen administration relative to pramlintide injection. Pramlintide significantly increased acetaminophen Tmax (range 48 to 72 minutes) when acetaminophen was administered simultaneously with or up to 2 hours following pramlintide injection, but it had negligible effect when acetaminophen was administered 1 to 2 hours before pramlintide injection.

MANAGEMENT: When rapid onset of a concomitantly administered oral medication is critical to its effectiveness, the medication should be administered at least 1 hour before or 2 hours after pramlintide injection.

References (1)
  1. (2005) "Product Information. Symlin (pramlintide)." Amphastar Pharmaceuticals Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer